justbacked

Biotechnology, Health Care, Life Science

Lycia Therapeutics

Lycia Therapeutics raised $75M in a Series D announced on Jun 25, 2026, led by Franklin Templeton, Eli Lilly, Janus Henderson Investors, Redmile Group, Balyasny Asset Management. Since then it has posted 6 roles (6 still open), the first 22 days after it. Another 1 open role was posted before the announcement. With 7 open roles it is hiring more than 9% of the 67 Series D+ startups on JustBacked (median: 48). In total it has raised $302M over 4 rounds from 16 investors.

Roles posted per month since the round
  • July 20261
  • October 20262
  • November 20263

From Lycia Therapeutics's own hiring system, by posting date. Tracked since Aug 21, 2026; roles that closed before then aren't counted.

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.

Why join Lycia Therapeutics?

The bet: that drugs can remove disease-causing proteins circulating in the blood or on cell surfaces, not just block them. If it pays off, Lycia Therapeutics of South San Francisco turns its modular biotech platform into treatments for a broad range of diseases, including some once considered undruggable. A $75M Series D from Eli Lilly, Franklin Templeton and Redmile Group, on $302M raised, backs the next phase, with three clinical roles open.

JustBacked's take, based on Lycia Therapeutics's own site and its funding and hiring data.

Series D · $75M · 149d agolyciatx.com

Hiring velocity

Open roles
7
Added, 30 days
+5
Added, 7 days
+3
Closed, 30 days
1
Raised
149 days ago
Led by
Franklin Templeton, Eli Lilly, Janus Henderson Investors, Redmile Group, Balyasny Asset Management
Team size
11-50
HQ
South San Francisco, California, United States
Newest role
3d ago
Tracked since
Aug 21, 2026

Where they're hiring

Clinical2
Operations2
Science1

Open roles at Lycia Therapeutics

Source: jobs.lever.co, checked daily.